Dapagliflozin in Pulmonary Arterial Hypertension
- Sponsor
- Mads Ersbøll
- Study ID
- NCT05179356
- Phase
- PHASE2
- Status
- Completed
Conditions
- Chronic Thromboembolic Pulmonary Hypertension
- Pulmonary Arterial Hypertension
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Dapagliflozin 10 MG [Farxiga] — DRUGDapagliflozin 10 mg given once daily for three months
- Placebo — DRUGMatching placebo
Study Details
The purpose of this study is to investigate the effects of dapagliflozin on exercise capacity and hemodynamics in patients with pulmonary arterial hypertension
Key Dates
- Start date
- Jan 1, 2023
- Status verified
- Jan 2026
- Primary completion
- Jan 13, 2026
- Completion
- Jan 13, 2026
Study Design
- Enrollment
- 52 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Dapagliflozin 10 mg once dailyDapagliflozin 10 mg (Farxiga 10 mg) given once daily for three months
- Placebo Comparator: Matching placeboPlacebo given once daily for three months
Primary Outcome Measure
Change in VO2 max from baseline to follow up [ Time Frame: 3 months ]
Related Studies
- Spironolactone for Pulmonary Arterial HypertensionPHASE2 · Recruiting · National Institutes of Health Clinical Center (CC) · Bethesda, Maryland
- Pediatric Pulmonary Hypertension Network (PPHNet) Informatics RegistryRecruiting · New York Medical College · Palo Alto, California
- A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionPHASE3 · Enrolling By Invitation · United Therapeutics · Phoenix, Arizona
- Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)Recruiting · V-Wave Ltd · Los Angeles, California